Climateer Line of the Day: Everyone's a Virologist Edition

Evercore analyst on the study in the NYT story below:

"This trial design reads pretty decent,” he wrote Monday. 

“However, the way in which results were reported 

(and omitted) makes it hard to draw definitive conclusions.”

—Evercore ISI's Umer Raffat as quoted in Barron's

 "Another Hydroxychloroquine Trial Still Leaves Questions on Its Use Against Covid-19"